ACKNOWLEDGEMENT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

DATE OF RELEASE/EXPIRATION

This activity was released on February 21, 2024 and is valid until February 21, 2025. Requests for credit must be made no later than February 21, 2025.

TARGET AUDIENCE

The educational design of this activity addresses the needs of managed care medical directors, hematologist-oncologists, and other clinicians involved in the management of patients with Chronic Lymphocytic Leukemia (CLL).

STATEMENT OF NEED/PROGRAM OVERVIEW

In the past decade, the emergence of targeted therapy with Bruton tyrosine kinase inhibitors (BTKIs) has changed the treatment landscape for chronic lymphocytic leukemia (CLL). While these advances have allowed clinicians to treat a wider array of patients, especially those for whom chemoimmunotherapy is not optimal, a need remains for clinicians to stay up to date with the latest guidelines and approvals of newer BTKIs for various CLL indications. Join a panel featuring an expert in CLL and a managed-care medical director to discuss newer BTKIs, how to select the most appropriate therapy for various patient profiles, how to monitor patients, and how to manage treatment-related adverse events. Panelists will discuss patient-centered treatment strategies that include identifying and selecting those patients who are most likely to benefit from BTKIs, as well as the significance of defining high-risk patients.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss the advantages of BTKIs over CIT for treatment of CLL and review guideline-based strategies for optimizing treatment
• Evaluate recent efficacy and safety data from clinical trials on second-generation BTKIs and determine their potential to provide targeted and safer treatment
• Outline CLL treatment plans based on BTKIs and considering each patient’s disease biology, genetic mutations, risk stratification, treatment response, and adverse events

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Association of Managed Care Nurses (AAMCN), National Association of Managed Care Physicians (NAMCP), and PlatformQ Health Education, LLC. NAMCP is accredited with commendation by the ACCME to provide continuing medical education to physicians.

PHYSICIAN CONTINUING EDUCATION

NAMCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). Nurses who complete this activity will receive up to 1 contact hour in nursing continuing professional development.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™ or NCPD contact hours, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

NAMCP requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to NAMCP policy. NAMCP is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Conflicts of Interest
John N. Allan, MD Associate Professor of Clinical Medicine Weill Cornell Medicine	Consulting Fee/Advisory Board: AbbVie, Adaptive, ADC Therapeutics, BeiGene, Epizyme, Genentech, Janssen, Lava, Lilly, Pharmacyclics Grant/Research Support: BeiGene, Celgene, Genentech Speakers Bureau/Honoraria: AbbVie, BeiGene, Janssen, Pharmacyclics
Gary M. Owens, MD President, Gary Owens Associates	Consultant: ICON, Magnolia Innovation, Payer Sciences Consulting Fee/Advisory Board: Baxter, BD, CVRx, OcuTerra, Octave Biosciences, Regeneron, Sanofi Employee/Owner: Gary Owens Associates, Inc.

The NAMCP planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please contact Jeremy Williams at jwilliams@namcp.org.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.